Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

ta show a 45 percent overall remission rate among patients treated with single agent clofarabine, with 40 percent of patients achieving a complete remission to therapy and 5 percent attaining a complete remission with incomplete platelet recovery. Overall remission in this study is defined as a patient achieving either complete remission or complete remission with incomplete platelet recovery. Secondary endpoints include duration of remission, disease free survival, overall survival, safety and thirty-day mortality. The CLASSIC II study data are based on clinical responses from 115 patients at 20 sites in the U.S.

Data also show overall remission rates of 50 percent among patients with prior blood disorders; 43 percent in patients with adverse cytogenetics; 40 percent in patients 70 years of age and older; and 38 percent in patients with an ECOG performance status of 2. Remission rates in patients with up to three pre-defined risk factors required for study enrollment also exceeded 40 percent.

The study also demonstrated that the toxicity profile of clofarabine was predictable and manageable. Drug-related adverse events occurring in more than 15 percent of patients included nausea, febrile neutropenia, vomiting, diarrhea and rash; most were grade 1 or 2. As expected, Grade 4 neutropenia and thrombocytopenia occurred in a majority of patients. Only five of 115 patients discontinued treatment due to an adverse event or toxicity precluding further therapy. The study has completed enrollment and patients are being followed for remission duration, disease-free survival and overall survival. An independent panel of hematologists and hematopathologists are confirming the investigators' assessment of responses.

"In addition to the excellent overall safety and efficacy findings we are observing with single agent clofarabine, we also see impressive responses in older patients with poor prognostic cytogenetic abnormalities when treated with the drug," stat
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... the Prox1 gene is a two-way switch that, if turne...programmed so that they lose their identity and be...MEMPHIS, Tenn., Dec. 1 ...al have discovered that a certain differentiated c...t requires the constant expression of a gene calle...
(Date:12/1/2008)...rk, December 1 Following...ntent to procure an MVA-based,third generation s...ces,Canada, on behalf of the Canadian Department ...varian Nordic for the delivery of IMVAMUNE(R). , ...UNE(R) as part of the,country,s bio-preparedness ...
(Date:12/1/2008)...RNewswire-FirstCall/ -- Vical Incorporated (Nasdaq...illion milestone payment from Merck & Co., Inc... clinical trial of an investigational plasmid DNA ...sed on Vical,s DNA gene delivery technology and en...T). hTERT is the subject of separate license agree...
(Date:11/28/2008)...y, November 28 German biotech comp...specialized HIV monitoring and,AIDS patient follo...ries. In,the year 2008, 2.5 million patient tests...d highly affordable "CyFlow" system, supporting al...AIDS. Due to introduction of the,Partec innovatio...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2First of its kind study compares high school knee injuries by sport and gender 20036 1First of its kind study compares high school knee injuries by sport and gender 20036 2Direct Response TV Course on Nutraceutical Cosmeceutical Products to Premiere in New York City 20034 1Direct Response TV Course on Nutraceutical Cosmeceutical Products to Premiere in New York City 20034 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 1Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 6American Lung Association Launches Online Photo Campaign to Expose Big Tobacco in Communities Nationwide 20032 1American Lung Association Launches Online Photo Campaign to Expose Big Tobacco in Communities Nationwide 20032 2
...ire-USNewswire/ -- Democratic,National Committee C... today after President Bush once again put politic...ch Enhancement Act of,2007. , The legislation, pro...tem cell research, has the overwhelming support of... Senate with,bipartisan support. A recent USA Toda...
...rs funded in part by the,National Institutes of He...st cases of Goltz syndrome, a rare skin disorder,t... cases appear to result from a defect in the gene ...ded to make a protein,referred to by researchers ...st identified in fruit flies, was named for the,pa...
Other Medicine Technology:Dean: President Bush Has Turned His Back on the American People 2Researchers Discover Gene For Rare Skin Disorder 2Researchers Discover Gene For Rare Skin Disorder 3
(Date:12/1/2008)...s goals, commitment and resources , , ...riticism that it has done a poor job safeguarding ...dministration released a report Monday detailing i...st important changes in 2008 was the agency,s init...d local health departments to protect the food sup...
(Date:12/1/2008)...er Institute,s cancer registry has found that as m...or incomplete radiation treatment following breast... can lead to worse outcomes. , Dr. Heather Taffe...gues found that among a nationally representative ...ents aged 65 and older, almost 1,300 women experie...
(Date:12/1/2008)...e/ -- Due to the urgent need to disseminate author...rch and clinical care, publisher Mary Ann Lieber...all archival online issues of the company,s AIDS j...rld AIDS Day. Free online access is available for ...m/apc ) and AIDS Research and Human Retroviruses...
(Date:12/1/2008)...wire/ -- Americans United for Life (AUL) today a...resolution opposing the federal "Freedom of Choice...pt the resolution immediately when they convene th... AUL President & CEO said, "The so-called ,Fre...protects and promotes the abortion industry, sacri...
Breaking Medicine News(10 mins):Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...y gave the all clear to 21 women who had breast ca... alter" their chances of fighting and surviving th...e cancer diagnosed two years after she was given a...ot being named by hospital bosses in Manchester. T...
...ffering from Motor Neurone Disease (MND), a fatal ...he use of a simple ventilator and facemask//. Pat...ould benefit from the new technique called non-inv...ping people with MND who suffer from weakness of t...
...e can increase the level of mental sharpness in ag...rs from University of Massachusetts at Lowell//. ...uice could protect against brain damage in aging m...to memory loss. Researcher Thomas B. Shea evaluate...
...mall group of patients can provide an adequate rep...uted by private health practitioners and their off...n Journal of General Internal Medicine. Highly co...vided by a group of 45 patients, according to the ...
Other Medicine News:
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: